# OnCo record nct02542293 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct02542293/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct02542293", "NCT02542293" ;
  schema:name "Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)"@en ;
  schema:alternateName "NEPTUNE"@en ;
  schema:description "A phase 3 trial of Durvalumab, Tremelimumab, Carboplatin, Gemcitabine + cisplatin, Gemcitabine and Cisplatin in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct02542293/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02542293> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2015-11-03" ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/tremelimumab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/gemcitabine-cisplatin/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/cisplatin/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> .